{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,23]],"date-time":"2026-07-23T02:10:07Z","timestamp":1784772607001,"version":"3.55.0"},"reference-count":29,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2022,9,17]],"date-time":"2022-09-17T00:00:00Z","timestamp":1663372800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2022,9,17]],"date-time":"2022-09-17T00:00:00Z","timestamp":1663372800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/501100005795","name":"Chang Gung Memorial Hospital, Linkou","doi-asserted-by":"publisher","award":["CPRPG3L0041"],"award-info":[{"award-number":["CPRPG3L0041"]}],"id":[{"id":"10.13039\/501100005795","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100005795","name":"Chang Gung Memorial Hospital, Linkou","doi-asserted-by":"publisher","award":["BMRPE22"],"award-info":[{"award-number":["BMRPE22"]}],"id":[{"id":"10.13039\/501100005795","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100008903","name":"Ministry of Health and Welfare","doi-asserted-by":"publisher","award":["MOHW110-TDU-B-212-124005"],"award-info":[{"award-number":["MOHW110-TDU-B-212-124005"]}],"id":[{"id":"10.13039\/100008903","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100004663","name":"Ministry of Science and Technology, Taiwan","doi-asserted-by":"publisher","award":["MOST 110-2628-B-182-013"],"award-info":[{"award-number":["MOST 110-2628-B-182-013"]}],"id":[{"id":"10.13039\/501100004663","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Nat Commun"],"abstract":"<jats:title>Abstract<\/jats:title><jats:p>Heterologous prime-boost COVID-19 vaccine strategy may facilitate mass COVID-19 immunization. We reported early immunogenicity and safety outcomes of heterologous immunization with a viral vector vaccine (ChAdOx1) and a spike-2P subunit vaccine (MVC-COV1901) in a participant-blinded, randomized, non-inferiority trial (NCT05054621). A total of 100 healthy adults aged 20\u201370 years having the first dose of ChAdOx1 were 1:1 randomly assigned to receive a booster dose either with ChAdOx1 (<jats:italic>n<\/jats:italic>\u2009=\u200950) or MVC-COV1901 (<jats:italic>n<\/jats:italic>\u2009=\u200950) at an interval of 4\u20136 or 8\u201310 weeks. At day 28 post-boosting, the neutralizing antibody geometric mean titer against wild-type SARS-CoV-2 in MVC-COV1901 recipients (236 IU\/mL) was superior to that in ChAdOx1 recipients (115\u00a0IU\/mL), with a GMT ratio of 2.1 (95% CI, 1.4 to 2.9). Superiority in the neutralizing antibody titer against Delta variant was also found for heterologous MVC-COV1901 immunization with a GMT ratio of 2.6 (95% CI, 1.8 to 3.8). Both spike-specific antibody-secreting B and T cell responses were substantially enhanced by the heterologous schedule. Heterologous boosting was particularly prominent at a short prime-boost interval. No serious adverse events occurred across all groups. The findings support the use of heterologous prime-boost with ChAdOx1 and protein-based subunit vaccines.<\/jats:p>","DOI":"10.1038\/s41467-022-33146-7","type":"journal-article","created":{"date-parts":[[2022,9,17]],"date-time":"2022-09-17T11:05:40Z","timestamp":1663412740000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":20,"title":["A randomized controlled trial of heterologous ChAdOx1 nCoV-19 and recombinant subunit vaccine MVC-COV1901 against COVID-19"],"prefix":"10.1038","volume":"13","author":[{"given":"Chih-Jung","family":"Chen","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6305-540X","authenticated-orcid":false,"given":"Lan-Yan","family":"Yang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9977-2267","authenticated-orcid":false,"given":"Wei-Yang","family":"Chang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yhu-Chering","family":"Huang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cheng-Hsun","family":"Chiu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shin-Ru","family":"Shih","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chung-Guei","family":"Huang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6891-6945","authenticated-orcid":false,"given":"Kuan-Ying A.","family":"Huang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2022,9,17]]},"reference":[{"key":"33146_CR1","unstructured":"Medicines & Healthcare productsRegulatory Agency. Conditions of Authorisation for COVID-19 Vaccine AstraZeneca (Regulation 174). https:\/\/www.gov.uk\/government\/publications\/regulatory-approval-of-covid-19-vaccine-astrazeneca\/conditions-of-authorisation-for-covid-19-vaccine-astrazeneca."},{"key":"33146_CR2","unstructured":"The New York Times. Tracking Coronavirus Vaccinations Around the World. https:\/\/www.nytimes.com\/interactive\/2021\/world\/covid-vaccinations-tracker.html (2022)."},{"key":"33146_CR3","unstructured":"UNICEF. COVID-19 Vaccine Market Dashboard. https:\/\/www.unicef.org\/supply\/covid-19-vaccine-market-dashboard (2022)."},{"key":"33146_CR4","doi-asserted-by":"publisher","first-page":"1979","DOI":"10.1016\/S0140-6736(20)32466-1","volume":"396","author":"MN Ramasamy","year":"2021","unstructured":"Ramasamy, M. N. et al. Safety and immunogenicity of ChAdOx1 nCoV-19 vaccine administered in a prime-boost regimen in young and old adults (COV002): a single-blind, randomised, controlled, phase 2\/3 trial. Lancet 396, 1979\u20131993 (2021).","journal-title":"Lancet"},{"key":"33146_CR5","doi-asserted-by":"publisher","first-page":"99","DOI":"10.1016\/S0140-6736(20)32661-1","volume":"397","author":"M Voysey","year":"2021","unstructured":"Voysey, M. et al. Safety and efficacy of the ChAdOx1 nCoV-19 vaccine (AZD1222) against SARS-CoV-2: an interim analysis of four randomised controlled trials in Brazil, South Africa, and the UK. Lancet 397, 99\u2013111 (2021).","journal-title":"Lancet"},{"key":"33146_CR6","doi-asserted-by":"publisher","first-page":"1646","DOI":"10.1016\/S0140-6736(21)00677-2","volume":"397","author":"E Vasileiou","year":"2021","unstructured":"Vasileiou, E. et al. Interim findings from first-dose mass COVID-19 vaccination roll-out and COVID-19 hospital admissions in Scotland: a national prospective cohort study. Lancet 397, 1646\u20131657 (2021).","journal-title":"Lancet"},{"key":"33146_CR7","doi-asserted-by":"publisher","first-page":"n1088","DOI":"10.1136\/bmj.n1088","volume":"373","author":"JL Bernal","year":"2021","unstructured":"Bernal, J. L. et al. Effectiveness of the Pfizer-BioNTech and Oxford-AstraZeneca vaccines on covid-19 related symptoms, hospital admissions, and mortality in older adults in England: test negative case-control study. Bmj 373, n1088 (2021).","journal-title":"Bmj"},{"key":"33146_CR8","doi-asserted-by":"publisher","first-page":"1027","DOI":"10.1080\/14760584.2021.1949294","volume":"20","author":"C-C Lai","year":"2021","unstructured":"Lai, C.-C. et al. COVID-19 vaccines and thrombosis with thrombocytopenia syndrome. Expert Rev. Vaccines. 20, 1027\u20131035 (2021).","journal-title":"Expert Rev. Vaccines."},{"key":"33146_CR9","doi-asserted-by":"publisher","first-page":"n1114","DOI":"10.1136\/bmj.n1114","volume":"373","author":"A Potteg\u00e5rd","year":"2021","unstructured":"Potteg\u00e5rd, A. et al. Arterial events, venous thromboembolism, thrombocytopenia, and bleeding after vaccination with Oxford-AstraZeneca ChAdOx1-S in Denmark and Norway: population based cohort study. Bmj 373, n1114 (2021).","journal-title":"Bmj"},{"key":"33146_CR10","doi-asserted-by":"publisher","first-page":"2124","DOI":"10.1056\/NEJMoa2104882","volume":"384","author":"NH Schultz","year":"2021","unstructured":"Schultz, N. H. et al. Thrombosis and Thrombocytopenia after ChAdOx1 nCoV-19 Vaccination. N. Engl. J. Med. 384, 2124\u20132130 (2021).","journal-title":"N. Engl. J. Med."},{"key":"33146_CR11","doi-asserted-by":"publisher","first-page":"100249","DOI":"10.1016\/j.lanepe.2021.100249","volume":"11","author":"P Nordstr\u00f6m","year":"2021","unstructured":"Nordstr\u00f6m, P., Ballin, M. & Nordstr\u00f6m, A. Effectiveness of heterologous ChAdOx1 nCoV-19 and mRNA prime-boost vaccination against symptomatic Covid-19 infection in Sweden: A nationwide cohort study. Lancet Regional Heal - Eur. 11, 100249 (2021).","journal-title":"Lancet Regional Heal - Eur."},{"key":"33146_CR12","doi-asserted-by":"publisher","first-page":"1255","DOI":"10.1016\/S2213-2600(21)00357-X","volume":"9","author":"D Hillus","year":"2021","unstructured":"Hillus, D. et al. Safety, reactogenicity, and immunogenicity of homologous and heterologous prime-boost immunisation with ChAdOx1 nCoV-19 and BNT162b2: a prospective cohort study. Lancet Respir. Med. 9, 1255\u20131265 (2021).","journal-title":"Lancet Respir. Med."},{"key":"33146_CR13","doi-asserted-by":"publisher","first-page":"1525","DOI":"10.1038\/s41591-021-01449-9","volume":"27","author":"J Barros-Martins","year":"2021","unstructured":"Barros-Martins, J. et al. Immune responses against SARS-CoV-2 variants after heterologous and homologous ChAdOx1 nCoV-19\/BNT162b2 vaccination. Nat. Med. 27, 1525\u20131529 (2021).","journal-title":"Nat. Med."},{"key":"33146_CR14","doi-asserted-by":"publisher","first-page":"1049","DOI":"10.1056\/NEJMc2110716","volume":"385","author":"J Normark","year":"2021","unstructured":"Normark, J. et al. Heterologous ChAdOx1 nCoV-19 and mRNA-1273 Vaccination. N. Engl. J. Med. 385, 1049\u20131051 (2021).","journal-title":"N. Engl. J. Med."},{"key":"33146_CR15","doi-asserted-by":"publisher","first-page":"36","DOI":"10.1016\/S0140-6736(21)02718-5","volume":"399","author":"A Stuart","year":"2022","unstructured":"Stuart, A. et al. Immunogenicity, safety, and reactogenicity of heterologous COVID-19 primary vaccination incorporating mRNA, viral-vector, and protein-adjuvant vaccines in the UK (Com-COV2): a single-blind, randomised, phase 2, non-inferiority trial. Lancet 399, 36\u201349 (2022).","journal-title":"Lancet"},{"key":"33146_CR16","doi-asserted-by":"publisher","first-page":"1396","DOI":"10.1016\/S2213-2600(21)00402-1","volume":"9","author":"S-M Hsieh","year":"2021","unstructured":"Hsieh, S.-M. et al. Safety and immunogenicity of CpG 1018 and aluminium hydroxide-adjuvanted SARS-CoV-2 S-2P protein vaccine MVC-COV1901: interim results of a large-scale, double-blind, randomised, placebo-controlled phase 2 trial in Taiwan. Lancet Respir. Med. 9, 1396\u20131406 (2021).","journal-title":"Lancet Respir. Med."},{"key":"33146_CR17","doi-asserted-by":"publisher","first-page":"E7348","DOI":"10.1073\/pnas.1707304114","volume":"114","author":"J Pallesen","year":"2017","unstructured":"Pallesen, J. et al. Immunogenicity and structures of a rationally designed prefusion MERS-CoV spike antigen. Proc. Natl Acad. Sci. 114, E7348\u2013E7357 (2017).","journal-title":"Proc. Natl Acad. Sci."},{"key":"33146_CR18","doi-asserted-by":"publisher","first-page":"eabe8065","DOI":"10.1126\/sciadv.abe8065","volume":"19","author":"PJ Klasse","year":"2021","unstructured":"Klasse, P. J., Nixon, D. F. & Moore, J. P. Immunogenicity of clinically relevant SARS-CoV-2 vaccines in nonhuman primates and humans. Sci. Adv. 19, eabe8065 (2021).","journal-title":"Sci. Adv."},{"key":"33146_CR19","unstructured":"Wold Health Organization. Solidarity Trial Vaccines. https:\/\/www.who.int\/emergencies\/diseases\/novel-coronavirus-2019\/global-research-on-novel-coronavirus-2019-ncov\/solidarity-trial-of-covid-19-vaccines (2021)."},{"key":"33146_CR20","doi-asserted-by":"publisher","first-page":"655","DOI":"10.3390\/vaccines10050655","volume":"10","author":"JA Estrada","year":"2022","unstructured":"Estrada, J. A. et al. An Immunobridging Study to Evaluate the Neutralizing Antibody Titer in Adults Immunized with Two Doses of Either ChAdOx1-nCov-19 (AstraZeneca) or MVC-COV1901. Vaccines (Basel) 10, 655 (2022).","journal-title":"Vaccines (Basel)"},{"key":"33146_CR21","doi-asserted-by":"publisher","first-page":"e0088321","DOI":"10.1128\/msphere.00883-21","volume":"7","author":"KT Liu","year":"2022","unstructured":"Liu, K. T. et al. Quantifying Neutralizing Antibodies in Patients with COVID-19 by a Two-Variable Generalized Additive Model [published online ahead of print, 2022 Feb 2]. mSphere 7, e0088321 (2022).","journal-title":"mSphere"},{"key":"33146_CR22","doi-asserted-by":"publisher","unstructured":"Kung, Y.-A. et al. Antibody titers measured by commercial assays are correlated with neutralizing antibody titers calibrated by international standards. Medrxiv https:\/\/doi.org\/10.1101\/2021.07.16.21260618 (2021).","DOI":"10.1101\/2021.07.16.21260618"},{"key":"33146_CR23","doi-asserted-by":"publisher","first-page":"100989","DOI":"10.1016\/j.eclinm.2021.100989","volume":"38","author":"S-M Hsieh","year":"2021","unstructured":"Hsieh, S.-M. et al. Safety and immunogenicity of a Recombinant Stabilized Prefusion SARS-CoV-2 Spike Protein Vaccine (MVC-COV1901) Adjuvanted with CpG 1018 and Aluminum Hydroxide in healthy adults: A Phase 1, dose-escalation study. Eclinicalmedicine 38, 100989 (2021).","journal-title":"Eclinicalmedicine"},{"key":"33146_CR24","doi-asserted-by":"publisher","first-page":"856","DOI":"10.1016\/S0140-6736(21)01694-9","volume":"398","author":"X Liu","year":"2021","unstructured":"Liu, X. et al. Safety and immunogenicity of heterologous versus homologous prime-boost schedules with an adenoviral vectored and mRNA COVID-19 vaccine (Com-COV): a single-blind, randomised, non-inferiority trial. Lancet 398, 856\u2013869 (2021).","journal-title":"Lancet"},{"key":"33146_CR25","doi-asserted-by":"publisher","first-page":"279","DOI":"10.1038\/s41591-020-01179-4","volume":"27","author":"JR Barrett","year":"2021","unstructured":"Barrett, J. R. et al. Phase 1\/2 trial of SARS-CoV-2 vaccine ChAdOx1 nCoV-19 with a booster dose induces multifunctional antibody responses. Nat. Med. 27, 279\u2013288 (2021).","journal-title":"Nat. Med."},{"key":"33146_CR26","doi-asserted-by":"publisher","first-page":"881","DOI":"10.1016\/S0140-6736(21)00432-3","volume":"397","author":"M Voysey","year":"2021","unstructured":"Voysey, M. et al. Single-dose administration and the influence of the timing of the booster dose on immunogenicity and efficacy of ChAdOx1 nCoV-19 (AZD1222) vaccine: a pooled analysis of four randomised trials. Lancet 397, 881\u2013891 (2021).","journal-title":"Lancet"},{"key":"33146_CR27","doi-asserted-by":"publisher","first-page":"eabj7211","DOI":"10.1126\/scitranslmed.abj7211","volume":"13","author":"PA Swanson 2nd","year":"2021","unstructured":"Swanson, P. A. 2nd et al. AZD1222\/ChAdOx1 nCoV-19 vaccination induces a polyfunctional spike protein-specific TH1 response with a diverse TCR repertoire. Sci. Transl. Med. 13, eabj7211 (2021).","journal-title":"Sci. Transl. Med."},{"key":"33146_CR28","doi-asserted-by":"publisher","first-page":"1041","DOI":"10.1126\/science.abn2688","volume":"375","author":"CI Kaku","year":"2022","unstructured":"Kaku, C. I. et al. Broad anti-SARS-CoV-2 antibody immunity induced by heterologous ChAdOx1\/mRNA-1273 vaccination. Science 375, 1041\u20131047 (2022).","journal-title":"Science"},{"key":"33146_CR29","doi-asserted-by":"publisher","first-page":"2029111","DOI":"10.1080\/21645515.2022.2029111","volume":"18","author":"N Wanlapakorn","year":"2022","unstructured":"Wanlapakorn, N. et al. Safety and immunogenicity of heterologous and homologous inactivated and adenoviral-vectored COVID-19 vaccine regimens in healthy adults: a prospective cohort study. Hum. Vaccin Immunother. 18, 2029111 (2022).","journal-title":"Hum. Vaccin Immunother."}],"container-title":["Nature Communications"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41467-022-33146-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41467-022-33146-7","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41467-022-33146-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,9,17]],"date-time":"2022-09-17T23:03:00Z","timestamp":1663455780000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41467-022-33146-7"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,9,17]]},"references-count":29,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2022,12]]}},"alternative-id":["33146"],"URL":"https:\/\/doi.org\/10.1038\/s41467-022-33146-7","relation":{},"ISSN":["2041-1723"],"issn-type":[{"value":"2041-1723","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,9,17]]},"assertion":[{"value":"17 February 2022","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"5 September 2022","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"17 September 2022","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare no competing interests.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"5466"}}